What is the right balance between ESA and IV iron in oncology patients?

1. Koch, C.G., Li, L., Sessler, D.I. et al. Duration od red-cell storage and complication after cardiac surgery. N. Engl. J. Med. 2008, 358, p. 1229-1239.

2. van Straten, A.H., Bekker, M.W., Hamad, M.A.S. et al. Transfusion of red blood cells: the impact on short-term and long-term survival after coronary artery bypass grafting, a ten-year follow-up. Interact. CardioVasc. Thorac. Surg. 2010, 10(1), p. 37-42.

3. Vamvakasn, E.C., Blajchman, M.A. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009, 113(15), p. 3406-3417.

4. Kiefmann, R., Rifkind, J.M., Nagababu, E., Bhattacharya, J. Red blood cells induce hypoxic lung inflammation. Blood 2008, 111(10), p. 5205-5214.

5. Reynolds, J.D., Ahearn, G.S., Angelo, M. et al. S-nitrosohemoglobin deficiency: A mechanism for loss of physiological activity in banked blood. Proc. Natl. Acad. Sci. 2007 104, p. 17058-17062.

6. Khorana, A.A., Francis, C.W., Blumberg, N. et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch. Intern. Med. 2008, 168(21), p. 2377-2381.

7. Glaspy, J.A. The development of erythropoietic agents in oncology. Expert. Opin. Emerg. Drugs 2005, 10(3), p. 553-567.

8. Glaspy, J.A. Erythropoietin in cancer patients. Annu. Rev. Med. 2009, 60, p. 181-192.

9. Bennett, C.L., Silver, S.M., Djulbegovic, B. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299(8), p. 914-924.

10. Weiss, G., Goodnough, L.T. Anemia of chronic disease. N. Engl. J. Med. 2005, 352, p. 43-55.

11. Auerbach, M., Ballard, H., Trout, J.R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 2004, 22, p. 1301-1307.

12. Hedenus, M., Birgegård, G., Näsman, P. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patient with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007, 21, p. 627-632.

13. Eschbach, J.W., Egrie, J.C., Downing, M.R. et al. Correction of the anemia of end‑stage renal disease with recombinant human erythropoetin: results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987, 316, p. 73–78.

14. Glaspy, J.A., Charu, V., Luo, D. et al. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer 2009, 115(5), p. 1121-1131.

15. Willmann, P.A., Dean, A. Retrospective review of total-dose iron dextran in iron-deficiency anemia of chronic disease and relevance to blood transfusion requirements: an individual institution experience. 50th Annual Meeting of American Society of Hematology, December 6-9, 2008, San Francisco, Poster No. 2876. Dostupný na http://ash. confex.com/ash/2008/webprogram/Paper3103.html.

16. Shord, S.S., Cuellar, S. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation. J. Am. Pharm. Assoc. 2008, 48(4), p. 487-493.

17. Auerbach, M., Winchester, J., Wahab, A. et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am. J. Kidney. Dis. 1998, 31, p. 81-86.

18. Rivera, S., Liu, L., Nemeth, E. et al. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005, 105, p. 1797-1802.

19. Sharma, S., Nemeth, E., Chen, Y.H. et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin. Cancer. Res. 2008, 14(11), p. 3262-3267.

20. Pedrazzoli, P., Farris, A., Del Prete, S. et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J. Clin. Oncol. 2008, 26(10), p. 1619-1625.

21. Bastit, L., Vandebroek, A., Altintas, S. et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 2008, 26(10), p. 1611-1618.

22. Beguin, Y., Maertens, J., De Prijck, B. et al. Darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter trial. Blood 2008, 112(11), p. 54.

23. Hedenus, M., Birgegard, G., Nasman, P. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patient with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007, 21, p. 627-632.

24. Dahl, N.V., Henry, D.H., Coyne, D.W. Thrombosis with erythropoietic stimulating agents – does iron-deficient erythropoiesis play a role? Semin. Dial. 2008, 21(3), p. 210-211.

25. Rizzo, J.D., Somerfield, M.R., Hagerty, K.L. et al. American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood 2008, 111(1), p. 25-41.

26. Aapro, M.S., Link, B. September 2007 Update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008,13(suppl 3), p. 33–36.

27. Mikhael, J., Melosky, B., Cripps, C. et al. Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr. Oncol. 2007, 14(5), p. 209–217.

28. Greenberg, P.L. Erythropoiesis-Stimulating Agent (ESA) treatment of MDS: controversies and perspectives. Hematologist 2007, 4(5), 2. Dostupné na www.hematology.org/Publications/Hematologist/2007/1115.aspx.

29. NICE technology appraisal guidance 142. Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancer-treatment induced anaemia. National Institute for Health and Clinical Excellence, 2008, 36 p. Dostupné na www.nice.org. uk/TA142.